8-K: Aura accelerates Phase 3; FY25 loss, runway to 2027

Aura Biosciences accelerated enrollment in its Phase 3 CoMpass trial, guided mid-2026 completion and 2H 2027 topline data, reported a wider FY25 net loss, and affirmed cash runway into Q1 2027.

Summary

• Guides mid-2026 completion of enrollment for the global Phase 3 CoMpass trial in early choroidal melanoma, with 15-month primary endpoint topline data expected in 2H 2027.
• Phase 1b/2 NMIBC (bladder cancer) trial progressing; initial 3-month clinical data expected mid-2026 across immune-ablative and neoadjuvant designs.
• New non-ocular formulation achieved 12-month stability; intended for simple refrigeration (no cold chain) and optimized for urology practice; related patent application, if issued, would provide coverage into 2046.
• Cash, cash equivalents and marketable securities totaled $144.2 million as of December 31, 2025; cash runway into the first quarter of 2027.
• R&D expenses were $21.9 million (Q4 2025) and $90.3 million (FY 2025) vs. $22.3 million (Q4 2024) and $73.3 million (FY 2024), reflecting Phase 3 CoMpass progression and personnel growth.
• G&A expenses decreased to $5.3 million (Q4 2025) and $22.5 million (FY 2025) from $5.5 million (Q4 2024) and $22.8 million (FY 2024).
• Net loss was $25.6 million (Q4 2025) and $106.2 million (FY 2025) vs. $25.8 million (Q4 2024) and $86.9 million (FY 2024).
• Regulatory tailwinds include FDA Fast Track and Orphan Drug Designations for early choroidal melanoma, EMA Orphan Drug Designation, and an FDA Special Protocol Assessment (SPA) for Phase 3 CoMpass.
• Additional ocular oncology programs: Phase 2 metastases to the choroid trial continues (early data expected in 2026) and a Phase 1 proof-of-concept trial for ocular surface cancers initiating in Australia (early data expected in 2026).
• Shares outstanding increased to 63,587,777 at December 31, 2025 (from 49,998,279 at December 31, 2024).

Sentiment

Score: 7

Explanation: StockSavvy.ai views the accelerated Phase 3 enrollment, multiple 2026 catalysts, and extended cash runway as constructive, offset by a wider net loss, long timelines to pivotal data, and typical clinical/regulatory risks.

Positives

• Accelerated global enrollment in Phase 3 CoMpass enables mid-2026 enrollment completion and 2H 2027 topline data, de-risking timelines for the lead program.
• Multiple regulatory advantages (FDA Fast Track and Orphan Drug; EMA Orphan Drug; FDA SPA) for early choroidal melanoma increase probability and clarity of the development path.
• New formulation for non-ocular tumors achieved 12-month stability with simple refrigeration and no cold chain, supporting in-office urology administration and potential IP protection into 2046.
• Pipeline breadth with ongoing trials in NMIBC, metastases to the choroid, and ocular surface cancers, with multiple 2026 readouts.
• G&A expense decreased year over year (FY 2025: $22.5 million vs. $22.8 million in FY 2024), indicating operating discipline.
• Cash and marketable securities of $144.2 million at year-end 2025 support operations into Q1 2027.

Negatives

• FY 2025 net loss widened to $106.2 million (from $86.9 million in FY 2024) on higher R&D investment.
• R&D expenses increased to $90.3 million in FY 2025 (from $73.3 million in FY 2024), elevating cash burn.
• Total assets declined to $169.4 million at December 31, 2025 (from $182.5 million at December 31, 2024).
• Interest income decreased to $6.6 million in FY 2025 (from $9.4 million in FY 2024).
• Clinical timelines remain long; Phase 3 topline data expected only in 2H 2027.
• No revenue and increasing accumulated deficit ($480.4 million) underscore funding dependency beyond the current cash runway.
• Shares outstanding rose to 63,587,777 (from 49,998,279), implying dilution over the year.

Risks

• Uncertainties inherent in clinical trials, including availability and timing of data and whether early or interim data predict final outcomes.
• Regulatory risks, including potential disagreement by authorities with clinical trial designs even under an SPA, and uncertainty around timing or receipt of approvals to conduct trials or market products.
• Risk that preclinical and clinical results may not be predictive of future studies and outcomes.
• Dependence on third-party collaborators and CROs to continue research, development, and manufacturing activities.
• Manufacturing scale-up risks for clinical and potential commercial supply.
• Financing risk that cash resources may not be sufficient for foreseeable and unforeseeable operating and capital needs.
• Enrollment, initiation, conduct, or completion risks for ongoing and planned clinical trials.
• Market size and commercialization risks, including the ability to successfully commercialize, if approved.
• Forward-looking guidance, including expected cash runway into Q1 2027, is subject to change due to factors outside of company control.

Future Outlook

Plans to complete Phase 3 CoMpass enrollment by mid-2026 with topline data in 2H 2027; expects initial 3-month data from the Phase 1b/2 NMIBC trial in mid-2026; anticipates early proof-of-concept data in 2026 for metastases to the choroid and ocular surface cancers; new stable formulation positions expansion into non-ocular solid tumors; cash runway guided into Q1 2027.

Management Comments

• “2025 has been a year of focused execution across our clinical portfolio, with significant progress in trial enrollment, highlighted by the acceleration of our global Phase 3 CoMpass trial in early choroidal melanoma and continued enrollment in our Phase 1b/2 NMIBC trial.”
• “Based on strong enrollment momentum, we now expect to complete CoMpass enrollment by mid-2026, with topline data anticipated in the second half of 2027.”
• “We are also encouraged by our new formulation reaching 12-month stability, further expanding our opportunity in non-ocular solid tumors, starting with urologic oncology.”

Industry Context

StockSavvy.ai notes that in early choroidal melanoma, standard-of-care plaque radiotherapy often compromises vision, and there are no approved vision-preserving drugs—positioning bel-sar as a potential first-in-class option if Phase 3 succeeds. In NMIBC, frontline care remains TURBT plus intravesical therapies, with BCG underperformance and high recurrence; while Adstiladrin (nadofaragene firadenovec) and pembrolizumab address BCG-unresponsive disease, a neoadjuvant, in-office, focal immune therapy could fill a meaningful gap if durable responses are shown.

Comparison to Industry Standards

• Regulatory pathway: An FDA Special Protocol Assessment for Phase 3 (CoMpass) is a favorable signal versus typical oncology registrational studies without SPA; peers in rare ophthalmic oncology (e.g., no direct competitors in early choroidal melanoma) generally lack such alignment.
• Clinical benchmarks (ocular): Standard radiotherapy for choroidal melanoma is associated with high rates of vision loss; bel-sar’s Phase 2 data cited 80% tumor control and 90% vision preservation in Phase 3–eligible patients at 12 months (small n), which compares favorably to historical vision outcomes if replicated at scale.
• Clinical benchmarks (NMIBC): Early Phase 1 data showed clinical complete responses in select intermediate/high-risk patients; by comparison, approved options like Adstiladrin (for BCG-unresponsive CIS) demonstrated meaningful CR rates but in a different, later-line setting—Aura’s neoadjuvant approach targets an earlier intervention and would need larger, longer-duration data for parity.
• Capital position: Year-end cash of $144.2 million with runway into Q1 2027 is in line with small/mid-cap clinical-stage biotech norms, though below larger peers (e.g., Immunocore) that fund multiple late-stage programs over longer horizons.
• Program breadth: Multi-indication platform development (ocular and urologic oncology) aligns with best practices in oncology platform companies seeking diversified value drivers, but execution risk scales with breadth.

Stakeholder Impact

• Shareholders: Extended runway into Q1 2027 reduces near-term financing pressure but widened losses and increased share count highlight dilution and funding risk beyond runway.
• Patients: Potential first-in-class, vision-preserving therapy in early choroidal melanoma and a novel neoadjuvant option in NMIBC could improve outcomes and quality of life if trials succeed.
• Employees/Operations: Continued R&D scaling, CRO engagement, and global trial execution signal ongoing resource demands and organizational growth.
• Partners/Suppliers: Increased clinical activity supports demand for CRO, manufacturing, and clinical site services; stability of new formulation simplifies logistics for urology practices.
• Creditors: Cash balance and runway support near-term obligations, though long-term funding needs remain contingent on clinical milestones.

Next Steps

• Complete global Phase 3 CoMpass enrollment by mid-2026.
• Deliver Phase 3 CoMpass topline data in 2H 2027 (15-month primary endpoint).
• Report initial 3-month clinical data from the Phase 1b/2 NMIBC trial in mid-2026.
• Provide early proof-of-concept data in 2026 for metastases to the choroid (Phase 2).
• Provide early proof-of-concept data in 2026 for ocular surface cancers (Phase 1, Australia).
• Advance non-ocular formulation toward broader urologic oncology applications and pursue patent protection (potential coverage into 2046 if issued).

Key Dates

Recommendation

Accelerated Phase 3 timelines, multiple 2026 readouts, and a de-risking SPA are positives, but the widened FY loss, extended path to pivotal data (2H 2027), and ongoing funding needs beyond Q1 2027 argue for a balanced stance pending clinical data inflections.

Keywords

bel-sar, AU-011, early choroidal melanoma, CoMpass trial, FDA Special Protocol Assessment, Fast Track, Orphan Drug, NMIBC, bladder cancer, virus-like drug conjugates, ocular oncology, urologic oncology, metastases to the choroid, ocular surface cancers, cash runway